| Pair Name | Artesunate, Cisplatin | ||
| Phytochemical Name | Artesunate (PubChem CID: 6917864 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Artesunate, Cisplatin | |||
| Disease Info | [ICD-11: 2C31.Z] | Head and neck squamous cell carcinoma | Investigative | |
| Gene Regulation | Down-regulation | Expression | RB1 | hsa5925 |
| Down-regulation | Phosphorylation | RB1 | hsa5925 | |
| In Vitro Model | UM-SCC-23 | Laryngeal squamous cell carcinoma | Homo sapiens (Human) | CVCL_7733 |
| UM-SCC-81B | Tonsillar squamous cell carcinoma | Homo sapiens (Human) | CVCL_7784 | |
| Result | These results suggested that artesunate is a useful drug in combination with cisplatin. | |||
| Pair Name | Artesunate, Cisplatin | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Up-regulation | Expression | CASP7 | hsa840 | |
| Up-regulation | Expression | CASP9 | hsa842 | |
| Down-regulation | Expression | CCNB1 | hsa891 | |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Down-regulation | Expression | GTF2H3 | hsa2967 | |
| Down-regulation | Phosphorylation | MAPK14 | hsa1432 | |
| Down-regulation | Phosphorylation | MAPK3 | hsa5595 | |
| Down-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| In Vivo Model | For a xenograft model, 1.0×10⁷/mL A-549 cell was injected into the right flanks of the five-week-old female nude mice (nu/nu) with weight of 13-16 g | |||
| Result | ART exhibited significant anti-tumor effect on A549 cells and this efficiency could be enhanced by combination with CIS | |||
| Pair Name | Artesunate, Cisplatin | |||
| Disease Info | [ICD-11: 2C9Z] | Urothelial carcinoma | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| In Vitro Model | HT-1376 | Bladder carcinoma | Homo sapiens (Human) | CVCL_1292 |
| BFTC-909 | Renal pelvis urothelial carcinoma | Homo sapiens (Human) | CVCL_1084 | |
| Result | Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells | |||
| No. | Title | Href |
|---|---|---|
| 1 | Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels. Oncol Rep. 2023 Aug;50(2):154. doi: 10.3892/or.2023.8591. | Click |
| 2 | Artesunate exhibits synergistic anti-cancer effects with cisplatin on lung cancer A549 cells by inhibiting MAPK pathway. Gene. 2021 Jan 15;766:145134. doi: 10.1016/j.gene.2020.145134. | Click |
| 3 | Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells. Anticancer Res. 2023 Mar;43(3):1175-1184. doi: 10.21873/anticanres.16263. | Click |
